Drug Database
Back to search

Japan· JP-7219416H2030

イオベルソール

A ioversol product containing イオベルソール, registered in Japan by ゲルベ・ジャパン, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

On Japan’s NHI price listATC V08AB07

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedイオベルソールATCV08AB07REGISTER NO.JP-7219416H2030PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about イオベルソールAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ioversol is registered in 14 of 19 countries.

Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 7 of them publish a price we can compare per daily dose
Search ioversol products by name

Ioversol · ATC V08AB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
イオベルソール
Manufacturer
ゲルベ・ジャパン
Country
Japan (JP)
ATC code
V08AB07
ATC class
Ioversol
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

188 interactions on record for ioversol.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ioversol against other medicinesHow interaction checks work

Ioversol · interactions on record

188 records

  • 94 severe
  • 55 moderate
  • 39 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ioversol in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ioversol products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Optiray
  • Belgium · Optiject, Optiray
  • Czechia · Optiray
  • Germany · Optiray
  • Denmark · Optiray
  • Spain · Optiray, Optiray Ultraject
  • Finland · Optiray
  • France · Optiject, Optiray
  • United Kingdom (Northern Ireland) · Optiray
  • Greece · Optiray
  • Croatia · Optiray
  • Hungary · Optiray
  • Ireland · Optiray
  • Italy · Optiray
  • Luxembourg · Optiject, Optiray
  • Netherlands · Optiray
  • Norway · Optiray
  • Poland · Optiray
  • Portugal · Optiray
  • Romania · Optiray
  • Sweden · Optiray
  • Slovakia · Optiray

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2f2d2342-06d8-4f8c-b6cf-6a2f3daf32d0
GET /v1/drugs/2f2d2342-06d8-4f8c-b6cf-6a2f3daf32d0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "７４．１％２０ｍＬ１瓶",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "7219416H2030",
  "category": "注射薬",
  "price_yen": 3567,
  "generic_name": "イオベルソール",
  "product_name_jp": null,
  "therapeutic_class": "7219",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about ioversol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console